Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2019, Vol. 39 Issue (12): 42-49    DOI: 10.13523/j.cb.20191206
技术与方法     
PD-L1基因敲除小鼠构建及初步表型验证
万颖寒1,慈磊3,*,王珏1,龚慧1,李俊1,董茹1,孙瑞林3,费俭2,3,沈如凌1,**()
1 模式生物及比较医学研究联合实验室 上海实验动物研究中心 上海 201203
2 同济大学生命科学与技术学院 上海 200092
3 上海南方模式生物科技股份有限公司 上海 201318
Construction and Preliminary Phenotypic Verification of PD-L1 Knockout Mice
WAN Ying-han1,CI Lei3,*,WANG Jue1,GONG Hui1,LI Jun1,DONG Ru1,SUN Rui-lin3,FEI Jian2,3,SHEN Ru-ling1,**()
1 Joint Laboratory of Model Biology and Comparative Medical Research,Shanghai Laboratory Animal Research Center,Shanghai 201210,China
2 School of Life Science and Technology, Tongji University, Shanghai 200092, China
3 Shanghai Model Organisms Center,Shanghai 201318,China
 全文: PDF(1686 KB)   HTML
摘要:

目的 程序性死亡配体-1(PD-L1)是免疫调节途径的重要因子,是抗肿瘤免疫疗法中重要的靶标之一。利用CRISPR/Cas9技术成功构建PD-L1基因敲除小鼠模型,并初步分析其表型。方法 构建Cas9和sgRNA载体,并转录获得RNA,通过显微注射方式将RNA注射到C57BL/6小鼠受精卵中,经过鉴定获得F0代阳性小鼠。F0代小鼠与野生型C57BL/6小鼠交配获得F1代杂合子小鼠,再通过F1代小鼠自交获得F2代纯合子小鼠品系。随后通过Real-Time PCR和流式实验分别检测PD-L1基因在mRNA和蛋白质水平上的表达情况。结果 Real-Time PCR和流式实验检测结果显示与野生型C57小鼠相比,PD-L1纯合子小鼠的PD-L1 mRNA相对表达水平和细胞上的蛋白质表达均有显著性下降,仅测定到本底的信号,证实已成功构建PD-L1基因敲除小鼠品系,为PD-L1体内基因功能研究提供了新的小鼠模型。

关键词: PD-L1PD-1CRISPR/Cas9基因敲除    
Abstract:

Objective: Programmed death ligand-1 (PD-L1) is an important factor in the immunoregulatory pathway and is one of the important targets in anti-tumor immunotherapy. The PD-L1 knockout mouse model was successfully constructed using CRISPR/Cas9 technology, and its phenotype was initially analyzed.Methods: Cas9 and sgRNA vectors were constructed and transcribed to obtain RNA. RNA was injected into C57BL/6 mouse fertilized eggs by microinjection, and F0 generation positive mice were obtained. F0 generation mice were mated with wild type C57BL/6 mice to obtain F1 generation heterozygous mice, and F2 generation homozygous mouse strains were obtained by self-crossing of F1 generation mice. Subsequently, the expression of PD-L1 gene at the mRNA and protein levels was detected by Real-Time PCR and flow cytometry, respectively.Results: Real-Time PCR and flow cytometry showed that the PD-L1 mRNA expression level and protein expression on PD-L1 homozygous mice with only background signals were significantly decreased, compared with wild-type C57 mice. It was confirmed that the PD-L1 knockout mouse strain was successfully constructed, which provided a new mouse model for PD-L1 gene function research in vivo.

Key words: PD-L1    PD-1    CRISPR/Cas9    Gene knockout
收稿日期: 2019-05-10 出版日期: 2020-01-15
ZTFLH:  Q78  
通讯作者: 慈磊,沈如凌     E-mail: shenruling@slarc.org.cn
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
万颖寒
慈磊
王珏
龚慧
李俊
董茹
孙瑞林
费俭
沈如凌

引用本文:

万颖寒,慈磊,王珏,龚慧,李俊,董茹,孙瑞林,费俭,沈如凌. PD-L1基因敲除小鼠构建及初步表型验证[J]. 中国生物工程杂志, 2019, 39(12): 42-49.

WAN Ying-han,CI Lei,WANG Jue,GONG Hui,LI Jun,DONG Ru,SUN Rui-lin,FEI Jian,SHEN Ru-ling. Construction and Preliminary Phenotypic Verification of PD-L1 Knockout Mice. China Biotechnology, 2019, 39(12): 42-49.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20191206        https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I12/42

图1  PD-L1基因敲除小鼠构建策略
图2  F0代小鼠基因型鉴定
  
图3  F2代小鼠基因型鉴定
图4  各基因型小鼠组织PD-L1 mRNA相对表达水平检测
图5  流式检测PD-L1基因敲除小鼠腹腔巨噬细胞和脾脏细胞PD-L1表达
[1] Shi Y Y . Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immun, 2018,67(10):1481-1489.
[2] Keir M E, Butte M J, Freeman G J , et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008,26:677-704.
[3] Dong H D, Strome S E, Matteson E L , et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest, 2003,111(3):363-370.
[4] Yamazaki T, Akiba H, Iwai H , et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol, 2002,169(10):5538-5545.
[5] Dong H D, Chen X M . Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol, 2006,3(3):179-187.
[6] Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology, 2007,19(7):813-824.
[7] Dong H D, Zhu G F, Tamada K , et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999,5(12):1365-1369.
[8] Dong H D, Strome S E, Salomao D R , et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med, 2002,8(8):793-800.
[9] Terawaki S, Chikuma S, Shibayama S , et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol, 2011,186(5):2772-2779.
[10] Brown J A, Dorfman D M, Ma F R , et al. Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol, 2003,170(3):1257-1266.
[11] Azuma T, Yao S, Zhu G , et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008,111(7):3635-3643.
[12] Hofmeyer K A, Jeon H, Zang X X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.[2011-9-25].
[13] Tsushima F, Yao S, Shin T , et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 2007,110(1):180-185.
[14] Yang B, Liu T J, Qu Y , et al. Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers. Front Oncol, 2018,8:563.
[15] Armand P . Immune checkpoint blockade in hematologic malignancies. Blood, 2015,125(22):3393-3400.
[16] Katz H, Wassie E, Alsharedi M . Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med Oncol, 2017,34(10):170.
[17] Buttner R, Gosney J R, Skov B G , et al. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol, 2017,35(34):3867.
[18] Weber J S ,D’Angelo S P,Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2015,16(4):375-384.
[19] Wainberg Z A, Hochster H S, George B , et al. Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) +/- gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. J Clin Oncol, 2017,35(4):412.
[20] El-Khoueiry A B, Melero I, Yau T C , et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. J Clin Oncol, 2018,36(4):475-475.
[21] Fuchs C S ,Doi T,Jang R W J, et al.KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patientsx with previously treated advanced gastric cancer. JAMA Oncol.[2018-3-15].
[22] Homet Moreno B, Ribas A . Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer, 2015,112(9):1421-1427.
[23] Topalian S L, Drake C G, Pardoll D M . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 2015,27(4):450-461.
[1] 武秀知,王宏杰,祖尧. 斑马鱼hoxa1a基因调控颅面骨骼发育的功能研究*[J]. 中国生物工程杂志, 2021, 41(9): 20-26.
[2] 赵梦泽,李凤智,王鹏银,李剑,徐寒梅. PD-L1和VEGF双靶点联合阻断治疗的研究进展[J]. 中国生物工程杂志, 2021, 41(9): 71-77.
[3] 毕博,张宇,赵慧. 酵母杂交系统在CRISPR/Cas9基因编辑系统脱靶率研究中的应用*[J]. 中国生物工程杂志, 2021, 41(6): 27-37.
[4] 郭洋,陈艳娟,刘怡辰,王海杰,王成稷,王珏,万颖寒,周宇,奚骏,沈如凌. Pd-1基因敲除小鼠构建及初步表型验证[J]. 中国生物工程杂志, 2021, 41(10): 1-11.
[5] 彭海丽,侯占铭. MDT1基因参与禾谷镰刀菌分生孢子发生和营养生长 *[J]. 中国生物工程杂志, 2020, 40(8): 10-18.
[6] 郭洋,万颖寒,王珏,龚慧,周宇,慈磊,万志鹏,孙瑞林,费俭,沈如凌. Toll样受体4(TLR4)基因剔除小鼠构建及初步表型分析[J]. 中国生物工程杂志, 2020, 40(6): 1-9.
[7] 郭晶,侯占铭. Folpcs1基因对尖孢镰刀菌亚麻专化型的无性繁殖和营养生长的调控 *[J]. 中国生物工程杂志, 2020, 40(3): 48-64.
[8] 郭胜楠, 李信晓, 王峰, 刘昆梅, 丁娜, 扈启宽, 孙涛. 海马与新皮质组织特异性GABRG2基因敲除小鼠模型的构建及其在遗传性癫痫伴热性惊厥附加症中的初步研究 *[J]. 中国生物工程杂志, 2020, 40(3): 9-20.
[9] 黄胜, 严启滔, 熊仕琳, 彭弈骐, 赵蕊. 基于CRISPR/Cas9-SAM系统CHD5基因过表达慢病毒载体的构建及对膀胱癌T24细胞增殖,迁移和侵袭能力的影响 *[J]. 中国生物工程杂志, 2020, 40(3): 1-8.
[10] 雷海英,赵青松,白凤麟,宋慧芳,王志军. 利用CRISPR/Cas9鉴定玉米发育相关基因ZmCen*[J]. 中国生物工程杂志, 2020, 40(12): 49-57.
[11] 王玥,牟彦双,刘忠华. 基于CRISPR/Cas系统的单碱基编辑技术研究进展*[J]. 中国生物工程杂志, 2020, 40(12): 58-66.
[12] 王伟东,杜加茹,张运尚,樊剑鸣. CRISPR/Cas9在人病毒感染相关疾病治疗研究中的应用*[J]. 中国生物工程杂志, 2020, 40(12): 18-24.
[13] 何秀娟,胡凤枝,刘秋丽,刘玉萍,祝玲,郑文云. 乳腺癌细胞QSOX1的CRISPR/Cas9基因编辑及其对增殖侵袭的影响研究*[J]. 中国生物工程杂志, 2020, 40(11): 1-9.
[14] 王志敏,毕美玉,贺佳福,任炳旭,刘东军. CRISPR/Cas9系统的发展及其在动物基因编辑中的应用 *[J]. 中国生物工程杂志, 2020, 40(10): 43-50.
[15] 吝建华,韩君,徐寒梅. PD-1/PD-L1免疫检查点抗体药物制剂稳定性开发[J]. 中国生物工程杂志, 2020, 40(10): 35-42.